|  |
| Kaiser study results on ranibizumab and bevacizumab
| A Kaiser Permanents Southern California study published in this month?s Ophthalmology, the journal of the American Academy of Ophthalmology, compares ranibizumab (Lucentis) and bevacizumab (Avastin) and found them to be equally effective in halting vision loss. | | | First ever sham-controlled study of radiation therapy for wet AMD initiated by Oraya Therapeutics
| | )? Oraya Therapeutics, Inc., announced today that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD). The groundbreaking clinical trial is being conducted at seven European sites, and will include a minimum of 150 patients, with approximately one third of those receiving a sham exposure and the remainder receiving radiation dosing of either 16 or 24 Gray (GY). | | | Visudyne evaluation indicates positive results
| | Positive twelve-month primary analysis results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with wet age-related macular degeneration (wet AMD) have been announced by QLT Inc. | | | Gene genie collaboration
| | A new collaboration between Oxford BioMedica and Sanofi-Aventis is to develop and commercialise gene therapy treatments for retinal degenerative diseases such as Stargardt disease, the form of early-onset macular degeneration and Usher syndrome, a relatively rare genetic disease where sufferers are born deaf and lose vision within the first 10 years of life. | | | The IOL-VIP system: restoring sight to AMD patients
| | Dr José Luis Menezo looks at improving the visual acuity of patients with age-related macular degeneration (AMD) using an IOL-Vip system. | | | Treating wet AMD with radiation
| | A single procedure may be as effective as repeated anti-VEGF injections claims Timothy L. Jackson. | | | Eye drops: a breakthrough in dry AMD treatment?
| | Paul Sternberg assesses the new approaches and exciting pipeline of potential dry AMD treatments. | | | Retina 2007
| | Take a look at what happened in the Retina field in 2007 and what exciting developments are round the corner in 2008. | | | Experience with Avastin in a UK clinic
| | A UK team reports how they achieved significant reductions in macular thickness by using intravitreal bevacizumab. | |  MORE ARTICLES
|
| |
| Implantable telescope finally gets FDA approval
| | VisionCare&#;s implantable telescope for end-stage AMD has finally been given FDA approval. The device, discussed in depth in Ophthalmology Times Europe July 2007, was given CE approval three years ago but has subsequently been undergoing rigorous clinical trials in the United States. | | | IRay stereotactic radiotherapy system gets European CE mark
| | Oraya Therapeutics has been granted the CE mark for its IRay system, which its researchers say can deliver low-energy X-rays to treat wet AMD. | | | First ever sham-controlled study of radiation therapy for wet AMD initiated by Oraya Therapeutics
| | )? Oraya Therapeutics, Inc., announced today that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD). The groundbreaking clinical trial is being conducted at seven European sites, and will include a minimum of 150 patients, with approximately one third of those receiving a sham exposure and the remainder receiving radiation dosing of either 16 or 24 Gray (GY). | | | Cancer drug no different in effectiveness as gold standard treatment for macular degeneration
| | Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). | | | Early AMD associated with coronary heart disease
| | The results of a study published in the July issue of Ophthalmology has discovered that people in the early stages of age-related macular degeneration (AMD) are at a higher risk of developing coronary heart disease (CHD), offering further support to the theory that AMD is associated with underlying systemic vascular disease. | | | AMD prediction a step closer using nature or nuture variables
| | Prevalence and incidence of advanced AMD can be catergorized as 'nature' or 'nurture' using a prediction model, based on genetic, environmental and demographic variables. | | | AMD biological marker discovered
| | A biological marker for neovascular age-related macular degeneration (AMD) has been discovered by a team of researchers from the University of Kentucky. | | | Dr Ambati wins 2010 ARVO award
| | Dr Jayakrishna Ambati, professor and vice chairman of Ophthalmology and Visual Sciences at the University of Kentucky, has been chosen to receive the 2010 Cogan Award from The Association for Research in Vision and Opthalmology (ARVO). | | | Question mark over Novartis combination therapy
| | The twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study investigating the efficacy and safety of combining Visudyne (Novartis Pharma AG) and Lucentis (Novartis Pharma AG, Genentech Inc.) have been released and so far are showing no significant differences. | | | MORE ARTICLES
|
| |
| |
| |
| Eyes on Oman
| More than 150 participants from 27 countries attended this year's SCHWIND User Meeting in Muscat, Oman. | | | Local anaesthesia for cataract surgery
| | A comparative evaluation of local anaesthesia for cataract surgery, published in The Journal of Cataract & Refractive Surgery says that randomized clinical trials are needed to facilitate statistical methods of metaanalysis to establish convincingly the overall benefits and efficacy of the various local anesthesia procedures in cataract surgery. | | | Schwind PresbyMAX treats presbyopia with excimer surgery
| | Schwind unveiled its PresbyMAX software module at ESCRS, a presbyopia solution for its AMARIS system. According to Schwind, the software makes it possible, for the first time, to treat emmetropic as well as myopic, hyperopic and astigmatic patients whose accommodative response is limited. | | | New approach to presbyopia treament
| | This is the first ESCRS congress for 9-month old company, Technolas, which was formed out of a joint venture between Bausch and Lomb's refractive surgery unit and 20/10 Perfect Vision. The new business was founded to innovate in excimer and femtosecond laser technologies, focusing primarily on the correction of presbyopia. | | | Technique intra-operative findings and postoperative regimen
| | Technique intra-operative findings and postoperative regimen | | | Combined cataract and vitreoretinal surgery
| | Combind cataract and vitreoretinal surgery | | | Cataract surgery in patients with pre-existing AMD: Risks and Benefits
| | Cataract surgery in patients with pre-existing AMD: Risks and Benefits | | | Toric IOL enhances refractive outcomes
| Rayner, the world's first IOL manufacturer, unveiled a dynamic new brand identity at ESCRS and held a seminar today to highlight the success doctors are having with its range of toric IOLs. Headlined A Roadmap to Success the seminar featured presentations from seven European doctors relating their experiences of using Rayner's toric IOLs. | | | Breakthrough micro-lens treatment for presbyopia
| The Flexivue System, a breakthrough implantable micro-lens treatment for presbyopia from Presbia Coöperatief was unveiled at the show and it is keenly anticipated that it will be in clinical trials in several European countries by the end of the year. | | | MORE ARTICLES
| | |
| |
| Local anaesthesia for cataract surgery
| | A comparative evaluation of local anaesthesia for cataract surgery, published in The Journal of Cataract & Refractive Surgery says that randomized clinical trials are needed to facilitate statistical methods of metaanalysis to establish convincingly the overall benefits and efficacy of the various local anesthesia procedures in cataract surgery. | | | Clinical trials show promise to help mydriasis during cataract surgery
| | Results from the Omeros Corporation for the Phase I/Phase II clinical trial of OMS302, a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) are said to be promising. | | | Researchers uncover genetic link to age-related cataracts
| | Researchers in Cleveland have discovered the first gene associated with the formation of age-related cataracts. EphA2 encodes an enzyme that plays a role in the repair of proteins in the lens of the eye after they become damaged and clump together, according to the investigators. | | | Ketolorac tromethamine should be available in September
| | Allergan Inc. expects its ketorolac tromethamine ophthalmic solution 0.45% (Acuvail) to be available in the United States in September. The preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the treatment of pain and inflammation after cataract surgery and received FDA approval at the end of July, the company announced. | | | Post cataract surgery pain treatment gets thumbs up
| | ACUVAIL (Allergan), the ketorolac tromethamine ophthalmic solution, which acts as a treatment for inflammation and pain after cataract surgery has been approved by the FDA. | | | Phacoemulsification fluidics characterized by new lab methods
| | Implementation of novel techniques to analyze the fluidic signature of phacoemulsification performed using different ultrasound modalities and phaco tips is providing important insights that will be helpful for improving the efficiency and safety of lens removal surgery. | | | Cataract surgery pipeline
| | The cataract surgery technology landscape including pipeline products at varying development stages comes under scrutiny in a new report released this month. | | | IOL receives further $40 million investment
| | Visiogen is reporting significant progress in the development of the Synchrony IOL, including the completion of the US phase III study, the formation of Visiogen Europe GmbH and the commencement of commercialization in Europe. | | | Managing post-PRK discomfort
| | When treating post-phacorefractive keratectomy (PRK) discomfort, there are no significant differences in either safety or efficacy between bromfenac twice-daily and ketorolac four times daily, according to a study published in the February issue of the Journal of Refractive Surgery. | | | MORE ARTICLES
|
| |
| |
| |
| Femtosecond gets thumbs up from Pallikaris
| | Femtosecond lasers provide a safe and effective way to create corneal flaps and tunnels, explained Professor Ionannis Pallikaris. | | | It's all changing at Zeiss
| | Recent acquisitions, division restructuring, and management changes prove that Carl Zeiss Meditec is very much committed to change. Ophthalmology Times Europe spoke with CEO, Dr Michael Kaschke about the challenges that he faces in an ever evolving market. | | | Seiler vs Holladay: the presbyopia debate
| | The search for a presbyopic treatment that is universally effective and universally applicable is viewed in the industry and the profession as the holy grail because of the number of people in the presbyopic age group today. | | | Femtosecond benefits in corneal procedures
| | Dr Rudi Nujits, presented new research on femtosecond laser assisted Descemet Stripping Endothelial Keratoplasty (FS-DSEK) at a session on the femtosecond laser and therapeutic corneal surgery. | | | Moria introduces single-use cataract instruments
| | The "One" range of single-use ophthalmic instruments has been introduced by Moria. The range comprises instruments commonly used during cataract surgery; instruments are available individually, or as part of a custom pack. | | | Volk launches high resolution wide field lens
| | Volk Optical has launched the H-R Wide Field Laser Lens, a pan-retinal lens intended for diagnosis and PRP laser treatment. | | | | Femtosecond to fully replace microkeratome
| | The age of microkeratomes is coming to an end as femtosecond lasers come of age. That's the chief conclusion drawn by Dr Gunther Grabner, professor of ophthalmology at the Paracelsus University of Salzburg, in a survey on the advantages and limitations of femtosecond lasers. | | | Dry eye diagnostic coming to a clinic near you
| | OcuSense, makers of the innovative TearLab Osmolarity System for the diagnosis of dry eye, announced the signing of multi-year agreements with four distributors in five EU countries, for the exclusive distribution of the TearLab system. | | | Oertli proud of new 1.6 mm tip
| | Oertli proudly showcased their new product that enables coaxial microincision cataract surgery through 1.6 mm: the CO-MICS 2 tip is fully compatible with the firm's existing OS3, SwissTech and CataRhex platforms. | | | MORE ARTICLES
|
| |
| Berlin Beckons
| | Join OTE in booth BL10 at this year's ESCRS congress |
| | Thank you!
| | Although we have always received a steady stream of feedback from readers, contributors and industry, never have we been bombarded by so many compliments in such a short space of time as at two recent conferences. | | | What do you want to see in OTE in 2009?
| | Fill in OTE's online readership survey for the chance to win €500 Marriott hotel vouchers. | | | The industry's evolving, so are we
| | Sometimes I sit back and think about how this magazine has evolved over the years and, on a more regular basis, I think about where we can go from here. | | | Micro innovations
| | In technological terms, when a word is prefixed by 'micro' you come to expect that word to signify some form of technological innovation or advance. In ophthalmology, the word 'microincision' represents significant advancement, particularly in the fields of cataract and vitreoretinal surgery. | | | World Glaucoma Day 2008: uniting to make a difference
| | The lack of public knowledge about glaucoma surprises me. Although pretty much everybody has heard of it, little is generally known other than the fact that it affects the eye. | | | LASIK: some still in the dark
| | I recently attended a party where I was drawn into a conversation by some people who had one thing in common – LASIK. Somebody amongst the group had undergone the procedure six years ago (incidentally, that was my sister) whilst another underwent wavefront-guided LASIK just weeks prior. Each of the four people had a story to tell about their experience with the procedure but, overall, each claimed they were happy with the end result. | | | Tempted by a free trip for two?
| | Tempted? | | | We invite you to have your say
| | When we launched Ophthalmology Times Europe (OTE) two years ago, our aim was always to provide a forum for ophthalmologists to communicate their knowledge, discoveries, experience and opinions. This aim has not changed. However, with the industry evolving at such a dramatic rate, it is difficult to convey the views and opinions of everyone who wants to be heard in our print publication. Help is at hand. | | | MORE ARTICLES
|
| |
| |
|
Glaucoma innovation for end of 2010
| | The French EyeOP1 medical device, from EyeTechCare, is a novel and non-invasive treatment for glaucoma that is based on the use of high-intensity focused ultrasound (HIFUs). The product is set to become available at the end of 2010 | | | World Glaucoma Day
| | Glaucoma remains the world's leading cause of irreversible blindness, but 50% of people who have this devastating disease don't know it,” said Dr Clive Midgal, president of the European Glaucoma Society. | | | Innovative glaucoma research award
| | The Glaucoma Research Foundation (GRF) awarded the 2010 Shaffer Prize for Innovative Glaucoma Research to Kate Keller, PhD. Dr Keller is Research Assistant Professor, Department of Ophthalmology at Casey Eye Institute in Portland, Oregon. | | | New study demonstrates potential for improving glaucoma diagnosis across Europe
| | Research claims that imaging devices can effectively support ophthalmologists with glaucoma diagnosis | | | Alcon acquires Optonol
| | Alcon acquires Optinol and enters glaucoma surgical market. | | | Scottish Medicines Consortium accepts first preservative-free ophthalmic prostaglandin
| | The Scottish Medicines Consortium (SMC) has announced that Saflutan (tafluprost) has been accepted for restricted use within NHS Scotland for the reduction of elevated intraocular pressure (IOP) in open angle glaucoma and ocular hypertension | | | Santen CEO joins Glaucoma Research Foundation
| | Adrienne Graves, CEO of Santen Inc., has been appointed to the Glaucoma Research Foundation?s board of directors. | | | New generation of diagnostic ultrasound system unveiled
| | Ellex Medical Lasers Ltd. unveiled the latest version of its diagnostic ultrasound system (Eye Cubed) at the recent annual meeting of the American Academy of Ophthalmology. | | | Laser system for treatment of glaucoma gets European patent approval
| | The IOPtiMate laser-based system, from the Bio-Light Group, used for the non-invasive filtration treatment of glaucoma has received European Patent Office approval. | | | MORE ARTICLES
|
| |
| Bausch & Lomb Introduces the Crystalens Aspheric Optic (AO) Lens
| | Crystalens AO is the first aberration-free accommodating IOL | | | Novel scleral lens proves cost-effective
| | In the December issue of the American Journal of Ophthalmology Brandeis University researchers published a paper about the highly precise scleral lens, to treat severe cornea or ocular surface disease, the Boston Ocular Surface Prosthesis (BOS-P). | | | IOL evolution for presbyopia
| | “As we move into the 21st century the role of the IOL will evolve allowing better outcomes in cataract surgery and find new roles in surgery to improve vision such as through the treatment of presbyopia.” | | | Partnering multifocal IOLs with LASIK to achieve perfect vision
| | Without performing LASIK, 85-90% of [multifocal IOL] patients may achieve spectacle independence. However, with LASIK success rates are about 99% | | | IOL implantation in children
| | The desired refractive outcome is approximately 2 D by age two and 1 to 2 D by age three, reflecting the fact that the majority of growth of the eye has occurred by this age | | | Can a MICS IOL also be a Toric IOL?
| | MICS is no longer just a more modern and innovative therapeutic option for cataract; it is also the best choice when offering refractive solutions. | | | Mix & match your way to better vision
| | By mixing and matching diffractive and refractive IOLs, patients can achieve much better all round visual results. | | | Vivarte IOL: good refractive results but withdrawn over safety concerns
| | Correction of very high myopia, i.e. above –9.00 D, remains a controversial topic and new designs of phakic IOLs have spurred great interest in the past five years. Presently, long-term results are becoming available and some interesting conclusions can be drawn, explained Matteo Piovella, MD, who reported his four-year results with one of these lenses at the XXIV Congress of the European Society of Cataract and Refractive Surgeons in London. | | | Investigational phakic IOL: examining the evidence
| | The AcrySof angle-supported phakic refractive IOL (Alcon) continues to offer patients with high myopia stable and accurate refractive results with excellent visual acuity (VA), according to physicians speaking at the XXIV Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in London last September. | | | MORE ARTICLES
|
| |
| 60 years of pioneering IOL innovation
| | Rayner Intraocular Lens Limited, has marked a milestone with a celebration to honour the 60th anniversary of the implantation of the first intraocular lens (IOL) in a patient. The late Sir Harold Ridley implanted the first IOL on 29 November 1949 at St. Thomas Hospital in London. Due to the controversial nature of the surgery, this first surgery was conducted in almost total secrecy. | | | Novel scleral lens proves cost-effective
| | In the December issue of the American Journal of Ophthalmology Brandeis University researchers published a paper about the highly precise scleral lens, to treat severe cornea or ocular surface disease, the Boston Ocular Surface Prosthesis (BOS-P). | | | Multifocal IOLs
| | Have a closer look at some of the multifocal IOLs available in Europe. | | | Monofocal IOLs
| | Take a look at some of the Monofocal IOLs available in Europe. | | | Accommodating IOLs
| | Accommodating IOLs are making a splash in Europe - why don't you take a closer look at some of them? | | | Phakic IOLs
| | Look at some of the Phakic IOLs that have been making a name for themselves in Europe. | | | MORE ARTICLES
|
| |
| Point of care tear film test simplifies dry eye management
| | Diagnosing and managing dry eye patients can be challenging. Here Dr Philipp Steven looks at a new way of treating tear film osmolarity, the TearLab Osmolarity System, which he believes could dramatically simplify the process. | | | Clinical improvement in adenoviral conjunctivitis model
| | Foresight Biotherapeutics, Inc. has announced data from a pre-clinical study designed to assess the safety and efficacy of the topical administration of FST-100 in a highly regarded Ad5 NZW rabbit model of adenoviral conjunctivitis. | | | Novagali technologies allow greater drug access to the posterior of the eye
| | According to research analysts it is estimated that as little as five percent of a topically applied drug ever reaches the intraocular tissues due to drug loss as the result of tearing, lacrimal fluid-eye barriers, and blood-ocular barriers. | | | Liquid ocular bandage launched in Europe
| | BD OcuSeal Liquid Ocular Bandage, a fully synthetic protective barrier to be used for post-surgical, post-traumatic and non-traumatic ocular conditions, has been launched in Europe by BD Medical?Ophthalmic Systems. | | | Retisert implant in sympathetic ophthalmia
| | The fluocinolone acetonide (Retisert; Bausch & Lomb) surgical implant can prevent blindness in cases of sympathetic ophthalmia (SO), according to research at the University of Iowa, US. | | | Link between skin cancer and eye cancer
| | There is an association between uveal and a variety of skin melanomas, according to study results published in the March issue of Ophthalmology. | |
| | Uveitis study enters Phase IIa
| | ESBATech AG, a developer of antibody fragment therapeutics, has initiated a Phase IIa study in patients with acute anterior uveitis, designed to evaluate the safety, tolerability and clinical activity of topically applied ESBA105. | | | Causes of infectious scleritis
| | Fungus and microbial infection are the most common causes of infectious scleritis, according to study conclusions published in the February issue of Eye. | | | Anti-inflammatory enters Phase I/II
| | ESBA105, an anti-TNF alpha antibody fragment designed to reduce inflammation in patients undergoing cataract surgery, has begun a Phase Ib/IIa trial, according to an announcement from ESBATech AG, the antibody's developer. | | | MORE ARTICLES
|
| |
| Open your mind to a new philosophy
| | Didier Ducournau talks about the development and growth of the EVRS and on his personal vision for vitreoretinal surgeons.
| | | The Italian pioneers
| | Surgeons should not feel ashamed if they only manage to see a few patients, devotion to the patient and then to your practice is of paramount importance. Then, and only then, will you be doing your job well. | | | European Society of Ophthalmology: the first 50 years
| | Since its inception in 1956, the European Society of Ophthalmology (SOE) has grown from a small entity into a conglomerate of national ophthalmological societies from all 40 European countries, representing more than 40,000 European ophthalmologists. We speak with President Zdenek Gregor about the changing face of the society, the importance of collaboration and the way the society has adapted to an ever-evolving Europe. | | | Learning to work together
| | 1991 witnessed the birth of the European Society of Cataract and Refractive Surgeons (ESCRS); a new kind of society aimed at unifying specialists and societies across a number of disciplines throughout the continent. Society President, Professor Marie José Tassignon talks to OTE about her vision for the future. | | | MORE ARTICLES
|
| |
| Ellex reports profits up
| |
Ellex Medical Lasers has reported a 16% increase in profits for the year ended 30 June 2010. | | | The development of the femtosecond laser for cataract surgery: moving beyond phacoemulsification
| | The femtosecond cataract laser introduces a level of safety, efficacy and reproducibility that will benefit all cataract surgeons, according to Dr Zoltan Nagy of Hungary. | | | Novartis now officially Alcon's majority shareholder
| | Novartis and Nestlé have completed the purchase of around 156 million Alcon shares for a staggering $28.3 billion in cash, giving Novartis control of approximately 77% of Alcon?s outstanding shares. | | | Swedish team successfully implant synthetic corneas and restore vision
| | A Swedish team has successfully implanted biosynthetic corneas in a small human trial, in a clinical study first. | | | Under-eights sight at risk in later life if parents shun eye tests
| | According to a recent report there may be as many as a million children with an undetected vision defect due to around 70% of schools not providing eye screening. | |
| New at WaveTec
| | Thomas G. Frinzi is to become company President and Chief Executive Officer at WaveTec Vision. He replaces Tom Berryman who after a period of transition will be leaving the company to pursue other entrepreneurial ventures. | | | Alcon closes LenSx deal
| | Alcon, Inc. has received regulatory approval for its acquisition of LenSx Lasers, Inc. | | | Relation of body weight to glaucoma risk
| | A new study has found that for primary open-angle glaucoma (POAG) a higher body weight in women, in particular body mass index BMI, is not associated with higher risk of the disease. | | | The relationship between the cornea and the optic disc
| | A clinical study, published recently in Eye journal, looked at the relationship between the cornea and the optic disc and suggests that there is a structural relationship between the two | | | MORE ARTICLES
|
| |
| Dear Editor
| | In answer to the question: "What specifically makes SLT different
from ALT in its action?" we offer the following response: | | | An African expedition
| | I embarked on a memorable trip to Africa recently and, along with a wonderful team of skilled ophthalmologists and nurses, we set up two eye camps in Namibia and Zambia. Our mission was to study corneal thickness in native Africans so that we could, in the future, establish the relationship between corneal thickness and glaucoma in this population. | | | MORE ARTICLES
|
| |
| Highlights from AAO 2007
| | Read Ophthalmology Times' extensive coverage from the 2007 annual meeting in New Orleans, USA. | | | Highlights from the ESCRS Congress 2007
| | Read Ophthalmology Times Europe's extensive coverage from the 2007 annual meeting in Stockholm, Sweden. | | | IGS 2007 Meeting Highlights
| | Athens played host to the sixth annual International Glaucoma Society (IGS) congress, which ran from 28-31 March. Attended by more than 2,650 participants from around the world, the meeting earned the title of the most attended international glaucoma meeting ever held. | | | Meeting highlights from the AAO annual congress 2006, Las Vegas, 11-14 November
| | More prospective studies are needed to evaluate the role of diurnal and long-term intraocular pressure (IOP) function in glaucoma development and progression, according to Felipe A. Medeiros, MD, PhD, assistant professor of ophthalmology, University of California at San Diego, USA, speaking at the glaucoma subspecialty session. | | | Accommodating lenses: the solution to presbyopia
| | Howard Fine, MD, speaking at the ISRS/AAO symposium, believes that the answer to correcting presbyopia lies in accommodating lenses rather than multifocal intraocular lenses (IOLs). | | | Wavefront: many measurements, deep analysis, one cut
| | The carpenter's rule is measure twice, cut once. The wavefront aberrometry rule should be measure hundreds of times, then analysed, and then cut once, Dr Robert Iskander said. | | | Wavelight announces two IOL approvals
| | Wavelight has announced the receipt of two regulatory approvals for its intraocular lenses (IOLs), thus expanding its intraocular product range. | | | ECOS proving to be a useful tool for cataract surgeons in Europe
| | The use of foldable intraocular lenses (IOLs) in cataract surgery is a trend that is continuing to rise across Europe, according to Mats Lundstrom speaking at the Outcomes of Cataract and Refractive Surgery symposium. | | | B&L launches new stable tubing system
| | Bausch & Lomb has introduced a stable chamber tubing system, as a part of the new micro incision vacuum pack, to its Millennium Micro Incision Cataract Surgery (MICS) platform. | | | MORE ARTICLES
|
| |
| |
| |
| IQ 577 laser system now available to doctors
| | Iridex has commenced shipment of its IQ 577 laser systems which is designed to treat vision-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma. | | | A comparison of six OCT devices
| | In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study. | | | NicOx reacquires rights to PF-03187207 for glaucoma from Pfizer
| | NicOx S.A. has signed an agreement with Pfizer Inc to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open angle glaucoma and ocular hypertension. As part of this agreement, Pfizer has granted NicOx the right to access and use certain proprietary Xalatan (latanoprost) data. | |
| Implant with potential to permanently treat glaucoma
| | OcumatRx, an early stage company that is developing a medical device that represents a new concept for the permanent treatment of patients with glaucoma, has announced the successful completion of clinical trials for their first device with favourable preliminary safety and tolerability. | | | Clinical trials show promise to help mydriasis during cataract surgery
| | Results from the Omeros Corporation for the Phase I/Phase II clinical trial of OMS302, a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) are said to be promising. | | | Ketolorac tromethamine should be available in September
| | Allergan Inc. expects its ketorolac tromethamine ophthalmic solution 0.45% (Acuvail) to be available in the United States in September. The preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the treatment of pain and inflammation after cataract surgery and received FDA approval at the end of July, the company announced. | | | Post cataract surgery pain treatment gets thumbs up
| | ACUVAIL (Allergan), the ketorolac tromethamine ophthalmic solution, which acts as a treatment for inflammation and pain after cataract surgery has been approved by the FDA. | | | Alcon discontinues development of anecortave acetate for IOP reduction
| | Alcon Inc. announced it has discontinued development of anecortave acetate for the reduction of IOP associated with glaucoma. | | | Future of corneal tomography
| | CSO, which has a background in measuring and analysing the anterior corneal surface has extended its research to the posterior surface with its new device SIRIUS. | | | MORE ARTICLES
|
| |
| Inhibiting and regressing corneal neovascularisation
| | Interim results from a Phase II study by Gene Signal suggest that antisense oligonucleotide GS-101 is safe and effective at inhibiting abnormal corneal new blood vessel growth. | | | Lowering levels of arginase may halt progression of diabetic retinopathy
| | High levels of the enzyme arginase contributes to vascular eye damage, and therapies to lower its levels could halt progression of diabetic retinopathy (DR), according to researchers at the Medical College of Georgia (MCG) School of Medicine, USA. | | | The brain predicts what moving eyes will see
| | A new study conducted by researchers at the University of Aberdeen, Scotland, has found that the brain predicts the consequences of eye movement even before the eyes take in a new scene. | | | Glaucoma related to selenium levels
| | The pathology of glaucoma is likely to be related to the presence and levels of selenium, according to the results of a study published in the August issue of the British Journal of Ophthalmology. | | | Implant with potential to permanently treat glaucoma
| | OcumatRx, an early stage company that is developing a medical device that represents a new concept for the permanent treatment of patients with glaucoma, has announced the successful completion of clinical trials for their first device with favourable preliminary safety and tolerability. | | | When can an eye growth transform into melanoma?
| | According to a report in the August issue of Archives of Ophthalmology, there are eight factors that may predict whether a choroidal nevus-a benign, flat, pigmented growth inside the eye and beneath the retina-may develop into melanoma. | | | Researchers uncover genetic link to age-related cataracts
| | Researchers in Cleveland have discovered the first gene associated with the formation of age-related cataracts. EphA2 encodes an enzyme that plays a role in the repair of proteins in the lens of the eye after they become damaged and clump together, according to the investigators. | | | Clinical trials show promise to help mydriasis during cataract surgery
| | Results from the Omeros Corporation for the Phase I/Phase II clinical trial of OMS302, a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) are said to be promising. | | | Gene therapy delivers bonus results
| | Partial sections of vision were recently restored to a blind woman's retina through the use of gene therapy. | | | MORE ARTICLES
|
| |
| OTE at the WOC
| | The Ophthalmology TImes Europe team is looking forward to meeting many readers and customers at the Congress and to bringing you coverage of the event and new developments emerging from it. | | | Standardizing trauma terminology
| | A standardized language of trauma classification can have value for prognosis as well as description, according to Dr Dante Pieramici. | | | Should tear dysfunction be treated with nutritional supplements?
| | Nutritional supplements seem to make sense as a treatment of tear dysfunction, according to Marian Macsai, MD. Dr Macsai tempered her assertion with the observation that no objective trials have been performed to support the use of nutritional supplements in patients with tear deficiency. | | | Flying eye hospital gets new aeroplane
| | Orbis International, an international nonprofit humanitarian organization which operates the world"s only Flying Eye Hospital, is to upgrade from a DC-10-10 to a DC-10 Series 30 freighter airline, giving the project an extra 20 years of flying time. | | | Dancing from pole to pole for ocular trauma surgery success
| | In industrialized countries, ocular trauma is the second leading cause of blindness among the over 50s population and the leading cause of monocular blindness among the general population; thus representing an important social health problem. | | | Minimally invasive strabismus surgery vs the limbal approach
| | As with all medical disciplines, the goal of every surgeon is to perform surgery that is minimally invasive, in order to reduce the risk of unwanted complications and a poor postoperative appearance, and to increase patient comfort and satisfaction. | | | Using the CO2 laser in oculoplastic surgery
| | Over the past five years, we have successfully performed oculoplastic surgery on several hundred patients at the Belgian Ocular Laser Center (BOLC; www.BOLC.org) in Ghent, Belgium and, during this time, I have found the CO2 laser to provide an excellent alternative to the scalpel for treating the eyelids. Finally, we can offer bloodless surgery and improved outcomes. | | | Making waves in 2006
| | The wavefront guided approach has certainly yielded the best outcomes in my practice; patient satisfaction rate is very high, while the retreatment rate is extremely low at 2.3% | | | The life of an inspirational ophthalmologist
| | The surgeon does not change gloves in between cases but simply rinses with 0.5% chlorhexidine/70% isopropyl alcohol solution. Despite the simplicity of this, the rates of infection in Dr V hospitals is lower than US rates | | | MORE ARTICLES
|
| |
| Anterior and posterior capsulorhexis in children
| | Anterior and posterior capsulorhexis in children | | | Paediatric ophthalmology conference programme
| | The Egyptian Group of Paediatric Eye Surgery (EGPES) will be hosting the 4th International Symposium of Paediatric Ophthalmology, from 4th to 6th of November 2009, in Alexandria, Egypt. | | | A clinical conundrum
| | According to the J Pediatr Ophthalmol Strabismus 2009;46:238-240 optic disc oedema is a clinical conundrum which has potential to delay diagnosis and therefore treatment of idiopathic intracranial hypertension. | | | Link between ROP and haemangioma in low birth-weight infants discovered
| | In infants with birth weights of 1250 g, haemangiomas are associated with the development of retinopathy of prematurity (ROP), according to study data published in the March 2009 issue of Pediatrics. | | | US introduces law protecting children's vision
| | The Vision Care for Kids Bill of 2009, legislation to provide vision care to children without health insurance, has been introduced in the US after being approved both by the Senate and by the House of Representatives. | | | Treating paediatric glaucoma
| | Penetrating deep sclerectomy (combining deep sclerectomy with trabeculectomy) delivers promising intermediate results in the treatment of paediatric glaucoma, according to the conclusions of a study published in the January issue of Ophthalmology. | | | Long-term treatment of strabismus with Botox
| | A long-term course of injections of botulinum toxin ("Botox") offers a viable treatment for complicated strabismus, according to study results published in the December 2008 issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus. | | | Giving sight to the developing world
| OTE's Victoria Farrell interviews Cambodian paediatric ophthalmologist Phara Khauv to find out how an ORBIS initiative has impacted his practice in a vastly underserved country. | | | Good VA means good stereopsis in children
| | Postoperative visual acuity (VA) is the factor with the most significant impact on stereopsis in paediatric unilateral pseudophakic subjects, according to study results published online ahead of print by the British Journal of Ophthalmology. | | | MORE ARTICLES
|
| |
| |
| ICLs effective over long-periods
| | The use of implantable collamer lenses (ICLs) to correct moderate to high myopia can offer predictable and stable results over a long period of time, according to a report published in the July issue of Archives of Ophthalmology. | | | Light adjustable lenses offer stability of refraction
| | Residual myopic errors can be successfully corrected postoperatively by using light-adjustable lens technology (LAL) in cataract patients, concludes a study published online by Ophthalmology. | | | Presbyopia lens launch
| | Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology. | | | IOL receives further $40 million investment
| | Visiogen is reporting significant progress in the development of the Synchrony IOL, including the completion of the US phase III study, the formation of Visiogen Europe GmbH and the commencement of commercialization in Europe. | | | New offerings for the refractive surgeon
| | The Visante omni is the first system to combine OCT and Placido disk technologies, providing comprehensive anterior and posterior topography for improved patient selection and care. | | | Can violent games improve lazy eyes?
| | Scientists at New York's Rochester University say that playing violent video games may improve contrast sensitivity, which is often impaired by amblyopia. | | | Eye diseases in pre-school children more common than first thought
| | In what is believed to be the first comprehensive eye disease study among urban pre-schoolers, investigators writing in the April issue of the journal Ophthalmology report that while vision problems are rare, they are more common than once thought. | | | Advantages of aspheric aberration-free method
| | Patients in need of visual corrections whose vision is not affected by existing high-order aberrations (HOAs) may have an alternative to wavefront treatment using an aberration-free method. | | | Building artificial corneas
| | Insights gained from research into keratoconus using extremely intense x-rays could refine laser surgeries, including LASIK, and may one day even lead to the development of an artificial cornea, according to researchers at Cardiff University, UK. | |
| | MORE ARTICLES
|
| |
| |
| Ranibizumab injections in combination with laser therapy offers new treatment for DME
| | The Diabetic Retinopathy Clinical Research Network (DRCR.net) study, published in Ophthalmology online has shown that ranibizumab (Lucentis) injections, in combination with laser treatment has produced better vision results than in patients treated by laser alone for diabetic macular oedema (DME). | | | Gene genie for AMD and RP?
| | Retinitis pigmentosa and AMD may be the beneficiaries of a new tool for gene therapy that significantly increases gene delivery to cells in the retina. | | | New retinal navigation system gains approval
| | The NAVILAS laser system, as reported on in the OTE Digest back in May this year ( What is Retinal Navigation? ) has been given FDA approval. | | | Two Phase III Lucentis studies show promise for RVO
| | Two Phase III studies of Lucentis (ranibizumab injection) in macular oedema due to retinal vein occlusion (RVO), have shown, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections. Results from both trials were presented at the Retina Congress 2009 meeting. | | | A review of the role and efficacy of anti-VEGF therapy in macular disease
| | A review of the role and efficacy of anti-VEGF therapy in macular disease | | | Cataract surgery in patients with pre-existing AMD: Risks and Benefits
| | Cataract surgery in patients with pre-existing AMD: Risks and Benefits | | | Improving retinal examination speed and efficiency
| Canon Europe, revealed its new CX-1, a world first in retinal imaging technology for the first time at this year's ESCRS Congress. | | | A comparison of six OCT devices
| | In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study. | | | Lowering levels of arginase may halt progression of diabetic retinopathy
| | High levels of the enzyme arginase contributes to vascular eye damage, and therapies to lower its levels could halt progression of diabetic retinopathy (DR), according to researchers at the Medical College of Georgia (MCG) School of Medicine, USA. | | | MORE ARTICLES
|
| |
|
|
| 
